Chronic Hepatitis
Conditions
Keywords
HBV, Steatosis
Brief summary
This study aims to evaluate the prevalence and severity of hepatic steatosis in CHB and investigate the relationship between hepatic steatosis and viral load, liver biochemistry, liver fibrosis, and inflammation in CHB
Detailed description
This hospital-based cohort study will be conducted on 80 adult hepatitis B surface antigen (HBsAg) carriers presented to the Tropical Medicine and Gastroenterology outpatient clinic, at Sohag University Hospital Exclusion criteria Patients with serological evidence of HCV. HBV patients who had received or are currently under anti-viral therapy. Alcohol consumption. Decompensated liver disease. Patients with HCC. Patients are known to have another chronic liver disease (e.g. autoimmune hepatitis, primary biliary cirrhosis, Wilson's disease, Haemochromatosis, or drug-induced chronic hepatitis). Patients with contraindications to liver biopsy such as uncooperative patients, prothrombin time (PT) \>4 seconds more than control, INR greater than 1.6, platelets count \<100.000/mm3After taking informed written consent, the participants will be subjected to: Clinical evaluation: medical history and physical examination. Laboratory investigations: Complete blood count. Prothrombin time and concentration. Liver function tests Anti-HCV. HBeAg. HBV DNA. Abdominal ultrasonography Ultrasound-guided percutaneous liver biopsy
Interventions
DIAGNOSTIC_TESTLiver biopsy
liver biopsy were taken then evaluated by histopathological examination
Sponsors
Sohag University
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
Hepatitis B surface antigen (HBsAg) carriers presented to the Tropical Medicine and Gastroenterology outpatient clinic, at Sohag University Hospital
Exclusion criteria
Patients with serological evidence of HCV. HBV patients who had received or are currently under anti-viral therapy. Alcohol consumption. Decompensated liver disease. Patients with HCC. Patients are known to have another chronic liver disease (e.g. autoimmune hepatitis, primary biliary cirrhosis, Wilson's disease, Haemochromatosis, or drug-induced chronic hepatitis). Patients with contraindications to liver biopsy such as uncooperative patients, prothrombin time (PT) \>4 seconds more than control, INR greater than 1.6, platelets count \<100.000/mm3.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| prevalence of hepatic steatosis in CHB | January 2023 to july 2023 will be included in the study | Number of cases with hepatic steotosis in CHB |
| degree of hepatic steatosis in CHB | January 2023 to july 2023 will be included in the study | Mild, or Moderate or severe degree |
Countries
Egypt
Outcome results
None listed